{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T13:16:52Z","timestamp":1768569412100,"version":"3.49.0"},"posted":{"date-parts":[[2025,10,9]]},"group-title":"Neurology","reference-count":40,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Plasma p-tau217 is a promising biomarker for detecting incipient AD pathology, but direct comparison of different p-tau217 assays in community-based cohorts are limited.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>\n                    We evaluated two cohorts from southwestern Pennsylvania, USA; the MYHAT-NI sub-study, which included two-year longitudinal follow-up neuroimaging assessments of A\u03b2, tau, and cortical thickness; and the Human Connectome Project\/CoBRA, targeting a 50:50 split of self-identified Black and non-Hispanic White individuals. Plasma p-tau217 was measured using four different assays: Lumipulse, Johnson&amp;Johnson, ALZpath, and NULISA. A\u03b2 and tau pathologies were assessed with [\n                    <jats:sup>11<\/jats:sup>\n                    C]PiB PET and [\n                    <jats:sup>18<\/jats:sup>\n                    F]Flortaucipir PET, respectively. Clinical Dementia Rating (CDR) and Montreal Cognitive Assessment were used to assess cognitive performance.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 344 participants (MYHAT-NI: n=111, median age 76 [IQR: 72-80], 54% female; HCP\/CoBRA: n=234, median age 62 [IQR: 52-70], 65% female). All four p-tau217 assays exhibited moderate to strong cross-platform correlations (Spearman correlations of 0.40 \u2013 0.86), and statistically equivalent AUCs (of 0.84-0.90) for determining A\u03b2 positivity.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our findings showed strong equivalent performances of plasma p-tau217 assays to identify amyloid positivity across two highly diverse cohorts of community-dwelling older adults.<\/jats:p>\n                <\/jats:sec>","DOI":"10.1101\/2025.10.07.25337434","type":"posted-content","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T20:35:19Z","timestamp":1760042119000},"source":"Crossref","is-referenced-by-count":0,"title":["Head-to-head comparison of plasma p-tau217 immunoassays for incipient Alzheimer\u2019s disease in community cohorts"],"prefix":"10.64898","author":[{"given":"Rebecca A.","family":"Deek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wasiu G.","family":"Balogun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gallen","family":"Triana-Baltzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmuth C.","family":"Kolb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth","family":"Snitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann D.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2025101105550915000_2025.10.07.25337434v1.1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00361-6"},{"key":"2025101105550915000_2025.10.07.25337434v1.2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01005-8"},{"key":"2025101105550915000_2025.10.07.25337434v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03605-x"},{"key":"2025101105550915000_2025.10.07.25337434v1.4","doi-asserted-by":"publisher","DOI":"10.1038\/nature19323"},{"key":"2025101105550915000_2025.10.07.25337434v1.5","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2100708"},{"issue":"3","key":"2025101105550915000_2025.10.07.25337434v1.6","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1001\/jamaneurol.2023.5319","article-title":"Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology","volume":"81","year":"2024","journal-title":"JAMA Neurol"},{"key":"2025101105550915000_2025.10.07.25337434v1.7","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01925-w"},{"key":"2025101105550915000_2025.10.07.25337434v1.8","doi-asserted-by":"publisher","DOI":"10.1001\/JAMA.2020.12134"},{"key":"2025101105550915000_2025.10.07.25337434v1.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02074-w"},{"issue":"7","key":"2025101105550915000_2025.10.07.25337434v1.10","doi-asserted-by":"crossref","first-page":"e70409","DOI":"10.1002\/alz.70409","article-title":"Pittsburgh plasma p-tau217: Classification accuracies for autosomal dominant and sporadic Alzheimer\u2019s disease in the community","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2025101105550915000_2025.10.07.25337434v1.11","doi-asserted-by":"publisher","DOI":"10.1002\/ALZ.13525"},{"key":"2025101105550915000_2025.10.07.25337434v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5"},{"key":"2025101105550915000_2025.10.07.25337434v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00923-z"},{"key":"2025101105550915000_2025.10.07.25337434v1.14","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-021-02275-6"},{"issue":"5","key":"2025101105550915000_2025.10.07.25337434v1.15","doi-asserted-by":"crossref","first-page":"e70209","DOI":"10.1002\/alz.70209","article-title":"Plasma GFAP for populational enrichment of clinical trials in preclinical Alzheimer\u2019s disease","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2025101105550915000_2025.10.07.25337434v1.16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","year":"2021","journal-title":"Transl Psychiatry"},{"key":"2025101105550915000_2025.10.07.25337434v1.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000008081"},{"key":"2025101105550915000_2025.10.07.25337434v1.18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s13195-023-01296-5","article-title":"Performance of plasma A\u03b242\/40, measured using a fully automated immunoassay, across a broad patient population in identifying amyloid status","volume":"15","year":"2023","journal-title":"Alz Res Therapy"},{"key":"2025101105550915000_2025.10.07.25337434v1.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-12148-5"},{"issue":"4","key":"2025101105550915000_2025.10.07.25337434v1.20","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jagp.2024.09.015","article-title":"Where Do Plasma Biomarkers fit in With Current Alzheimer\u2019s Disease Detection?","volume":"33","year":"2025","journal-title":"Am J Geriatr Psychiatry"},{"key":"2025101105550915000_2025.10.07.25337434v1.21","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12514"},{"issue":"2","key":"2025101105550915000_2025.10.07.25337434v1.22","doi-asserted-by":"crossref","first-page":"fcad057","DOI":"10.1093\/braincomms\/fcad057","article-title":"Plasma phosphorylated tau 217 in preclinical Alzheimer\u2019s disease","volume":"5","year":"2023","journal-title":"Brain Commun"},{"key":"2025101105550915000_2025.10.07.25337434v1.23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s13195-025-01803-w","article-title":"Plasma biomarkers identify brain ATN abnormalities in a dementia-free population-based cohort","volume":"17","year":"2025","journal-title":"Alz Res Therapy"},{"issue":"3","key":"2025101105550915000_2025.10.07.25337434v1.24","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1007\/s11682-020-00334-2","article-title":"Alzheimer\u2019s disease pathology in a community-based sample of older adults without dementia: The MYHAT neuroimaging study","volume":"15","year":"2021","journal-title":"Brain Imaging Behav"},{"key":"2025101105550915000_2025.10.07.25337434v1.25","doi-asserted-by":"crossref","first-page":"669490","DOI":"10.3389\/fnagi.2021.669490","article-title":"Connectomics in Brain Aging and Dementia - The Background and Design of a Study of a Connectome Related to Human Disease","volume":"13","year":"2021","journal-title":"Front Aging Neurosci"},{"key":"2025101105550915000_2025.10.07.25337434v1.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42834-x"},{"key":"2025101105550915000_2025.10.07.25337434v1.27","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13024-024-00753-5","article-title":"Multi-analyte proteomic analysis identifies blood-based neuroinflammation, cerebrovascular and synaptic biomarkers in preclinical Alzheimer\u2019s disease","volume":"19","year":"2024","journal-title":"Mol Neurodegeneration"},{"key":"2025101105550915000_2025.10.07.25337434v1.28","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005549"},{"key":"2025101105550915000_2025.10.07.25337434v1.29","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12018"},{"key":"2025101105550915000_2025.10.07.25337434v1.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.265941"},{"key":"2025101105550915000_2025.10.07.25337434v1.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.08.005"},{"key":"2025101105550915000_2025.10.07.25337434v1.32","doi-asserted-by":"publisher","DOI":"10.1214\/15-EJS1035"},{"key":"2025101105550915000_2025.10.07.25337434v1.33","doi-asserted-by":"publisher","DOI":"10.1093\/BRAIN\/AWAC333"},{"issue":"2","key":"2025101105550915000_2025.10.07.25337434v1.34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/brain\/awae346","article-title":"A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests","volume":"148","year":"2025","journal-title":"Brain"},{"issue":"5","key":"2025101105550915000_2025.10.07.25337434v1.35","doi-asserted-by":"crossref","first-page":"e70166","DOI":"10.1002\/alz.70166","article-title":"Targeted proteomic biomarker profiling using NULISA in a cohort enriched with risk for Alzheimer\u2019s disease and related dementias","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2025101105550915000_2025.10.07.25337434v1.36","doi-asserted-by":"crossref","first-page":"e70535","DOI":"10.1002\/alz.70535","article-title":"Alzheimer\u2019s Association Clinical Practice Guideline on the use of blood-based biomarkers in the diagnostic workup of suspected Alzheimer\u2019s disease within specialized care settings","volume":"21","year":"2025","journal-title":"Alzheimers Dement"},{"key":"2025101105550915000_2025.10.07.25337434v1.37","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaa286"},{"key":"2025101105550915000_2025.10.07.25337434v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03400-0"},{"key":"2025101105550915000_2025.10.07.25337434v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02443-z"},{"issue":"6","key":"2025101105550915000_2025.10.07.25337434v1.40","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1038\/s41591-025-03617-7","article-title":"Plasma MTBR-tau243 biomarker identifies tau tangle pathology in Alzheimer\u2019s disease","volume":"31","year":"2025","journal-title":"Nat Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2025.10.07.25337434","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T20:48:01Z","timestamp":1768510081000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2025.10.07.25337434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1101\/2025.10.07.25337434","relation":{},"subject":[],"published":{"date-parts":[[2025,10,9]]},"subtype":"preprint"}}